<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35198967</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2590-2075</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>4</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biofilm</Title>
          <ISOAbbreviation>Biofilm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Synergistic effect of antibiotic combinations on <i>Staphylococcus aureus</i> biofilms and their persister cell populations.</ArticleTitle>
        <Pagination>
          <StartPage>100068</StartPage>
          <MedlinePgn>100068</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">100068</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioflm.2022.100068</ELocationID>
        <Abstract>
          <AbstractText>Treatment of staphylococcal infections is difficult due to multidrug resistance with their persister forms posing an added threat of recalcitrant infections. Antibiotic combinations are widely studied as an alternative strategy to combat them; therefore, they merit further investigation into their effect on the number of persister cells. In the present study, the fractional inhibitory concentrations of antibiotic combinations ciprofloxacin-daptomycin, ciprofloxacin-vancomycin, daptomycin-tobramycin, and tobramycin-vancomycin (checkerboard assay) were determined against two previously studied clinical (S48 and J6) and one standard (NCIM 5021) isolate of <i>Staphylococcus aureus.</i> They showed synergistic effects with a 2 to 256-fold reduction in MICs. All combinations also resulted in inhibition and disruption of biofilms in a concentration-dependent manner. All antibiotic combinations, except ciprofloxacin-daptomycin, showed total biofilm inhibition at 100X MICs. Similarly, antibiotic combination at 100X MIC showed 77-97% disruption of preformed biofilms. Time-kill assays performed at a 100X MIC combination against stationary-phase cells showed a two to six log<sub>10</sub> reduction in CFU followed by a plateau indicating the presence of persisters. Significant differences were observed in persister cell fraction remaining after treatment with antibiotic combinations compared to monotherapies (p &lt; 0.05) and therefore merit further investigation in clinical use for treatment against persisters.</AbstractText>
          <CopyrightInformation>© 2022 Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kamble</LastName>
            <ForeName>Ekta</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, Savitribai Phule Pune University, Ganeshkhind Road, Pune, 411 007, Maharashtra, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sanghvi</LastName>
            <ForeName>Purva</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, Savitribai Phule Pune University, Ganeshkhind Road, Pune, 411 007, Maharashtra, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pardesi</LastName>
            <ForeName>Karishma</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology, Savitribai Phule Pune University, Ganeshkhind Road, Pune, 411 007, Maharashtra, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biofilm</MedlineTA>
        <NlmUniqueID>101764202</NlmUniqueID>
        <ISSNLinking>2590-2075</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Biofilm</Keyword>
        <Keyword MajorTopicYN="N">Drug combination</Keyword>
        <Keyword MajorTopicYN="N">Drug tolerance</Keyword>
        <Keyword MajorTopicYN="N">Staphylococcus aureus</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35198967</ArticleId>
        <ArticleId IdType="pmc">PMC8844754</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bioflm.2022.100068</ArticleId>
        <ArticleId IdType="pii">S2590-2075(22)00002-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Geneva S.  World Health Organization; Geneva Switzerland: 2014. Antimicrobial resistance: global report on surveillance.</Citation>
        </Reference>
        <Reference>
          <Citation>Mulani M.S., Kamble E.E., Kumkar S.N., Tawre M.S., Pardesi K.R. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol. 2019;10:539. doi: 10.3389/fmicb.2019.00539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2019.00539</ArticleId>
            <ArticleId IdType="pmc">PMC6452778</ArticleId>
            <ArticleId IdType="pubmed">30988669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ventola C.L. The antibiotic resistance crisis: causes and threats. PC Tech J. 2015;40:277–283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4378521</ArticleId>
            <ArticleId IdType="pubmed">25859123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis K. Persister cells and the paradox of chronic infections. Microbe. 2010;5:429–437. doi: 10.1146/annurev.micro.112408.134306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.micro.112408.134306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis K.  Springer International Publishing; 2019. Persister cells and infectious disease.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-030-25241-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keren I., Shah D., Spoering A., Lewis K. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol. 2004;186:8172–8180. doi: 10.1128/JB.186.24.8172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JB.186.24.8172</ArticleId>
            <ArticleId IdType="pmc">PMC532439</ArticleId>
            <ArticleId IdType="pubmed">15576765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan F., Pham D.T.N., Tabassum N., Oloketuyi S.F., Kim Y.M. Treatment strategies targeting persister cell formation in bacterial pathogens. Crit Rev Microbiol. 2020;46:665–688. doi: 10.1080/1040841X.2020.1822278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1040841X.2020.1822278</ArticleId>
            <ArticleId IdType="pubmed">33022189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fauvart M., de Groote V.N., Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol. 2011;60:699–709. doi: 10.1099/jmm.0.030932-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/jmm.0.030932-0</ArticleId>
            <ArticleId IdType="pubmed">21459912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wood T.K. Combatting bacterial persister cells; Combatting bacterial persister cells. Biotechnol Bioeng. 2016;113:476–483. doi: 10.1002/bit.25721/abstract.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bit.25721/abstract</ArticleId>
            <ArticleId IdType="pubmed">26264116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vazquez-grande G., Kumar A. Optimizing antimicrobial therapy of sepsis and septic shock. Focus on Antibiotic Combination Therapy. 2015;1:154–166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25643278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broussou D.C., Lacroix M.Z., Toutain P.-L., Woehrlé F., El Garch F., Bousquet-Melou A., et al.  Differential activity of the combination of vancomycin and amikacin on planktonic vs. Biofilm-growing Staphylococcus aureus bacteria in a hollow fiber infection model. Front Microbiol. 2018;9:572. doi: 10.3389/fmicb.2018.00572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2018.00572</ArticleId>
            <ArticleId IdType="pmc">PMC5880918</ArticleId>
            <ArticleId IdType="pubmed">29636741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamble E., Pardesi K. Antibiotic tolerance in biofilm and stationary-phase planktonic cells of Staphylococcus aureus. Microb Drug Resist. 2020 doi: 10.1089/mdr.2019.0425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/mdr.2019.0425</ArticleId>
            <ArticleId IdType="pubmed">32013708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doern C.D. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing downloaded from. 4124. JcmAsmOrg J Clin Microbiol. 2014;52:4124–4128. doi: 10.1128/JCM.01121-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01121-14</ArticleId>
            <ArticleId IdType="pmc">PMC4313275</ArticleId>
            <ArticleId IdType="pubmed">24920779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaidhani S.V., Raskar A.V., Poddar S., Gosavi S., Sahu P.K., Pardesi K.R., et al.  Time-dependent enhanced resistance against antibiotics &amp; metal salts by planktonic &amp; biofilm form of Acinetobacter haemolyticus MMC 8 clinical isolate. Indian J Med Res. 2014;140:665–671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4311322</ArticleId>
            <ArticleId IdType="pubmed">25579150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chopade B., Ghosh, Patil, Ahire, Kitture, Jabgunde, et al.  Synthesis of silver nanoparticles using Dioscorea bulbifera tuber extract and evaluation of its synergistic potential in combination with antimicrobial agents. Int J Nanomed. 2012;7:483. doi: 10.2147/ijn.s24793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/ijn.s24793</ArticleId>
            <ArticleId IdType="pmc">PMC3273981</ArticleId>
            <ArticleId IdType="pubmed">22334779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lechner S., Lewis K., Bertram R. Staphylococcus aureus persisters tolerant to bactericidal antibiotics. J Mol Microbiol Biotechnol. 2012;22:235–244. doi: 10.1159/000342449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000342449</ArticleId>
            <ArticleId IdType="pmc">PMC3518770</ArticleId>
            <ArticleId IdType="pubmed">22986269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Çokça F., Arman D., Altay G. In vitro activity of vancomycin combined with rifampin, amikacin, ciprofloxacin or imipenem against methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Clin Microbiol Infect. 1998;4:657–659. doi: 10.1111/j.1469-0691.1998.tb00349.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1469-0691.1998.tb00349.x</ArticleId>
            <ArticleId IdType="pubmed">11864265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baltch A.L., Ritz W.J., Bopp L.H., Michelsen P., Smith R.P. Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth. Antimicrob Agents Chemother. 2008;52:1829–1833. doi: 10.1128/AAC.01480-07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.01480-07</ArticleId>
            <ArticleId IdType="pmc">PMC2346650</ArticleId>
            <ArticleId IdType="pubmed">18332172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardesi A., Pable A., Bhagat D.S.S. Applications of metal nanoparticles to combat biofilm-forming ESKAPE pathogens. Recent Adv. Biotechnol. 2019:1–38.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu H., Moser C., Wang H.Z., Høiby N., Song Z.J. Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2015;7:1–7. doi: 10.1038/ijos.2014.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ijos.2014.65</ArticleId>
            <ArticleId IdType="pmc">PMC4817533</ArticleId>
            <ArticleId IdType="pubmed">25504208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciofu O., Rojo-Molinero E., Macià M.D., Oliver A. Antibiotic treatment of biofilm infections. APMIS. 2017;125:304–319. doi: 10.1111/apm.12673.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apm.12673</ArticleId>
            <ArticleId IdType="pubmed">28407419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barber K.E., Smith J.R., Ireland C.E., Boles B.R., Rose W.E., Rybaka M.J. Evaluation of ceftaroline alone and in combination against biofilm-producing methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin and vancomycin in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2015;59:4497–4503. doi: 10.1128/AAC.00386-15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00386-15</ArticleId>
            <ArticleId IdType="pmc">PMC4505217</ArticleId>
            <ArticleId IdType="pubmed">25987623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimura S., Sato T., Hayakawa S., Kawamura M., Furukawa E., Watanabe A. Antimicrobial efficacy of combined clarithromycin plus daptomycin against biofilms-formed methicillin-resistant Staphylococcus aureus on titanium medical devices. J Infect Chemother. 2015;21:756–759. doi: 10.1016/j.jiac.2015.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jiac.2015.06.001</ArticleId>
            <ArticleId IdType="pubmed">26162777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jorgensen S.C.J., Rybak M.J. Meropenem and vaborbactam: stepping up the battle against carbapenem-resistant enterobacteriaceae. Pharmacotherapy. 2018;38:444–461. doi: 10.1002/phar.2092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/phar.2092</ArticleId>
            <ArticleId IdType="pubmed">29427523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J., Mao N.-F., Wang L., Zhang H.-B., Chen Q., Liu H., et al.  Efficacy of combined vancomycin and fosfomycin against methicillin-resistant Staphylococcus aureus in biofilms in vivo. PLoS One. 2014;9 doi: 10.1371/journal.pone.0113133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0113133</ArticleId>
            <ArticleId IdType="pmc">PMC4281042</ArticleId>
            <ArticleId IdType="pubmed">25551618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cirioni O., Mocchegiani F., Ghiselli R., Silvestri C., Gabrielli E., Marchionni E., et al.  Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. Eur J Vasc Endovasc Surg. 2010;40:817–822. doi: 10.1016/j.ejvs.2010.08.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejvs.2010.08.009</ArticleId>
            <ArticleId IdType="pubmed">20869272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duffull S.  Vol. 73. 2012.  (Basic pharmacokinetics and pharmacodynamics, an integrated textbook and computer simulations).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2125.2011.04077.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D'Espine M., Bellido F., Pechère J.C., Auckenthaler R., Rohner P., Lew D., et al.  Serum levels of ciprofloxacin after single oral doses in patients with septicemia. Eur J Clin Microbiol Infect Dis. 1989;8:1019–1023. doi: 10.1007/BF01975162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01975162</ArticleId>
            <ArticleId IdType="pubmed">2620671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benvenuto M., Benziger D.P., Yankelev S., Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245. doi: 10.1128/AAC.00247-06.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00247-06</ArticleId>
            <ArticleId IdType="pmc">PMC1610083</ArticleId>
            <ArticleId IdType="pubmed">17005801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapter 5. Vancomycin | Applied Clinical Pharmacokinetics, 2e | AccessPharmacy | McGraw Hill Medical n.d. https://accesspharmacy.mhmedical.com/content.aspx?sectionid=40843073&amp;bookid=510 (accessed December 2, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>VandenBussche H.L., Homnick D.N. Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis. J Pediatr Pharmacol Ther JPPT. 2012;17:67. doi: 10.5863/1551-6776-17.1.67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5863/1551-6776-17.1.67</ArticleId>
            <ArticleId IdType="pmc">PMC3428189</ArticleId>
            <ArticleId IdType="pubmed">23118659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asghari B., Sadeghi H.R., Mazaherylaghab H. Combatting Bacterial Persister cell infections by auranofin? Biomed Pharmacother. 2017;96:1565–1566. doi: 10.1016/j.biopha.2017.07.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2017.07.022</ArticleId>
            <ArticleId IdType="pubmed">28716566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bojer M.S., Lindemose S., Vestergaard M., Ingmer H. Quorum sensing-regulated phenol-soluble modulins limit persister cell populations in Staphylococcus aureus. Front Microbiol. 2018;9:1–12. doi: 10.3389/fmicb.2018.00255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2018.00255</ArticleId>
            <ArticleId IdType="pmc">PMC5826201</ArticleId>
            <ArticleId IdType="pubmed">29515541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Breij A., Riool M., Cordfunke R.A., Malanovic N., de Boer L., Koning R.I., et al.  The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. Sci Transl Med. 2018;10:eaan4044. doi: 10.1126/scitranslmed.aan4044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aan4044</ArticleId>
            <ArticleId IdType="pubmed">29321257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Defraine V., Fauvart M., Michiels J. Fighting bacterial persistence: current and emerging anti-persister strategies and therapeutics. Drug Resist Updates. 2018;38:12–26. doi: 10.1016/j.drup.2018.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drup.2018.03.002</ArticleId>
            <ArticleId IdType="pubmed">29857815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W., Zhu W., Hendricks G.L., Van Tyne D., Steele A.D., Keohane C.E., et al.  A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature. 2018;556:103–107. doi: 10.1038/nature26157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature26157</ArticleId>
            <ArticleId IdType="pmc">PMC6462414</ArticleId>
            <ArticleId IdType="pubmed">29590091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W., Hendricks G.L., Tori K., Fuchs B.B., Mylonakis E. Strategies against methicillin-resistant Staphylococcus aureus persisters. Future Med Chem. 2018;10:779–794. doi: 10.4155/fmc-2017-0199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4155/fmc-2017-0199</ArticleId>
            <ArticleId IdType="pmc">PMC6077763</ArticleId>
            <ArticleId IdType="pubmed">29569952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt N.W., Deshayes S., Hawker S., Blacker A., Kasko A.M., Wong G.C.L. Engineering persister-specific antibiotics with synergistic antimicrobial functions. ACS Nano. 2014;8:8786–8793. doi: 10.1021/nn502201a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/nn502201a</ArticleId>
            <ArticleId IdType="pmc">PMC4173747</ArticleId>
            <ArticleId IdType="pubmed">25130648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conlon B.P., Nakayasu E.S., Fleck L.E., Lafleur M.D., Isabella V.M., Coleman K., et al.  Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature. 2013;503:365–370. doi: 10.1038/nature12790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12790</ArticleId>
            <ArticleId IdType="pmc">PMC4031760</ArticleId>
            <ArticleId IdType="pubmed">24226776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niu H., Cui P., Yee R., Shi W., Zhang S., Feng J., et al.  A clinical drug library screen identifies tosufloxacin as being highly active against Staphylococcus aureus persisters. Antibiotics. 2015;4:329–336. doi: 10.3390/antibiotics4030329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/antibiotics4030329</ArticleId>
            <ArticleId IdType="pmc">PMC4790289</ArticleId>
            <ArticleId IdType="pubmed">27025627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manoharan R.K., Mahalingam S., Gangadaran P., Ahn Y.H. Antibacterial and photocatalytic activities of 5-nitroindole capped bimetal nanoparticles against multidrug resistant bacteria. Colloids Surf B Biointerfaces. 2020;188 doi: 10.1016/j.colsurfb.2020.110825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.colsurfb.2020.110825</ArticleId>
            <ArticleId IdType="pubmed">32006909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tawre M.S., Kamble E.E., Kumkar S.N., Mulani M.S., Pardesi K.R. Antibiofilm and antipersister activity of acetic acid against extensively drug resistant Pseudomonas aeruginosa PAW1. PLoS One. 2021;16 doi: 10.1371/journal.pone.0246020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0246020</ArticleId>
            <ArticleId IdType="pmc">PMC7853517</ArticleId>
            <ArticleId IdType="pubmed">33529248</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
